Pharmaceutical

Thompson Street Capital Partners Portfolio Company Savillex Acquires Optimum Processing, Inc.

ST. LOUIS, Nov. 7, 2024 /PRNewswire/ -- Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis,…

2 months ago

Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness

News Summary: waters_connect™ Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development…

2 months ago

DarioHealth Reports Third Quarter 2024 Financial and Operating Results

Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111%…

2 months ago

Lexaria Updates Fast-Moving GLP-1 ‘Arm’s Race’ Developments

DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience…

2 months ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Revenue increased 31% for the quarter compared to same period prior yearPositive cash flows from operations of $0.35 million for…

2 months ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

2 months ago

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…

2 months ago

Promising cooperation between medac and chiron for the development of organ-on chip technology

WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development.…

2 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial…

2 months ago

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14,…

2 months ago